Renbing Jiang

Xinjiang Medical University - Affiliated Cancer Hospital

SCHOLARLY PAPERS

1

DOWNLOADS

34

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety and Efficacy of Pucotenlimab (HX008) - A Humanized Immunoglobulin G4 Monoclonal Antibody in Patients with Locally Advanced or Metastatic Melanoma: A Single-Arm, Multicenter, Phase II Study

Number of pages: 9 Posted: 02 Jun 2022
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Fujian Medical University - Fujian Cancer Hospital, Fudan University - Shanghai Cancer Center (FUSCC), Nanjing University - The Affiliated Drum Tower Hospital, Sichuan University - West China Hospital, Zhejiang University - Sir Run Run Shaw Hospital, The First Affiliated Hospital of Zhengzhou University, Jinan University, Tongji University - Shanghai Tenth People's Hospital, Xinjiang Medical University - Affiliated Cancer Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Taizhou Hanzhong Biomedical Co., Ltd. (A member of Lepu Biopharma Co., Ltd.), Jilin University (JLU) - First Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Taizhou Hanzhong Biomedical Co., Ltd. (A member of Lepu Biopharma Co., Ltd.), Taizhou Hanzhong Biomedical Co., Ltd. (A member of Lepu Biopharma Co., Ltd.), Jilin University (JLU) - First Hospital and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 34 (1,013,342)

Abstract:

Loading...

Pucotenlimab, HX008, Anti-PD-1 antibody, Melanoma, Phase II study